Adding Cytokines to Monoclonal Antibody Therapy: Does the Concurrent Administration of Interleukin-12 Add to the Efficacy of Rituximab in B-cell Non-Hodgkin Lymphoma?-Reference-Cited by-同舟云学术

Adding Cytokines to Monoclonal Antibody Therapy: Does the Concurrent Administration of Interleukin-12 Add to the Efficacy of Rituximab in B-cell Non-Hodgkin Lymphoma?

Published:2003-01 Issue:8 Volume:44 Page:1309-1315
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ansell Stephen M.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1042819031000083325

Reference44 articles.

1. CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin’s Lymphoma Predicts Patient Outcome

2. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

3. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

4. Interleukin 12: a new clinical player in cytokine therapy

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Checkpoint Blockade in Lymphoma;Journal of Clinical Oncology;2021-02-10

2. Rituximab (Rituxan®);Handbook of Therapeutic Antibodies;2014-08-12

3. Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies;Clinical Cancer Research;2011-01-01

4. Antitumor Antibodies in the Treatment of Cancer: Fc Receptors Link Opsonic Antibody with Cellular Immunity;Hematology/Oncology Clinics of North America;2006-06

5. Biological Therapy of Non-Hodgkin's Lymphomas;The Lymphomas;2006